New fixed-dose paediatric TB formulations now available for procurement through the Global Drug Facility
31 March 2016 – Geneva, Switzerland - The new fixed-dose paediatric formulations are now available for procurement through the Global Drug Facility (GDF): rifampicin 75 mg + isoniazid 50 mg + pyrazinamide 150 mg and rifampicin 75 mg + isoniazid 50. The products dissolve in water, have a fruit flavour, and are simple to administer.
Before initiating the procurement process, the National TB programmes are advised to read the attached Technical Briefing Note and complete the self-assessment check list (Annex 1) to evaluate their readiness for introduction of the new paediatric formulations.
In case the National TB programme needs technical assistance for development of a strategic plan for transition to the new paediatric formulations including update of the national medicine policy and regulation, forecasting, quantification, supply planning, etc., please do not hesitate to inform your GDF focal point.
If you would like to proceed with ordering the new paediatric formulations, please fill in the Procurement request form and send it to your focal point at GDF. The form is available on the GDF website here.
Technical Briefing Note and self-assessment check list (Annex 1)
Source: Stop TB Partnership
